{"id":94690,"date":"2023-12-26T15:39:57","date_gmt":"2023-12-26T10:09:57","guid":{"rendered":"http:\/\/finservwealth.com\/astrazeneca-to-buy-china-based-gracell-biotechnologies-in-1-2-billion-deal\/"},"modified":"2023-12-26T15:39:57","modified_gmt":"2023-12-26T10:09:57","slug":"astrazeneca-to-buy-china-based-gracell-biotechnologies-in-1-2-billion-deal","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/astrazeneca-to-buy-china-based-gracell-biotechnologies-in-1-2-billion-deal\/","title":{"rendered":"AstraZeneca to buy China-based Gracell Biotechnologies in $1.2 billion deal"},"content":{"rendered":"<p> The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.<\/p><div id=\"finse-1912505157\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/world-news\/astrazeneca-to-buy-china-based-gracell-biotechnologies3612-billion-deal_17379751.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met. The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/world-news\/astrazeneca-to-buy-china-based-gracell-biotechnologies3612-billion-deal_17379751.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/world-news\/astrazeneca-to-buy-china-based-gracell-biotechnologies3612-billion-deal_17379751.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met. The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/world-news\/astrazeneca-to-buy-china-based-gracell-biotechnologies3612-billion-deal_17379751.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-94690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2021\/200x200\/A\/ASTRAZENECA_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/94690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=94690"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/94690\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=94690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=94690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=94690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}